Therapeutics News

Clinicians should consider dupilumab as a therapeutic option for bullous pemphigoid due to its ability to clear blistering and pruritus safely, according to a study.

Healio has compiled June’s most-read news in dermatology.

IceCure Medical has received marketing authorization from the FDA for its next-generation single probe cryoablation system, the company announced in a press release.

The FDA has approved Sofdra gel 12.45% for the treatment of primary axillary hyperhidrosis in adults and children aged 9 years and older, Botanix Pharmaceuticals announced in a press release.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

CLEVELAND — Dermatomyositis treatment options could grow exponentially in the next few years, according to David Fiorentino, MD, PhD, professor of dermatology at Stanford University.

CLEVELAND — The Cleveland Clinic’s biannual Medical Dermatology Therapy Update meeting is currently underway, bringing news about medical therapies available in the dermatology space.

Isotretinoin is associated with a clinically marginal increased risk for severe adverse events, leading researchers to advise routine blood testing commence shortly after initiation, according to a study.

Almirall has entered into a licensing agreement with Eloxx Pharmaceuticals Inc. to develop and commercialize ZKN-013 for the treatment of orphan dermatological diseases, according to an Almirall press release.

AbbVie reported a worldwide net revenue of $12.31 billion in the first quarter of 2024 despite Humira sales dropping due to biosimilar competition, according to a company press release.